CD 47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer

@inproceedings{Weiskopf2016CD4I,
  title={CD 47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer},
  author={Kipp Weiskopf and Nadine S. Jahchan and Peter J. Schnorr and Sandra Cristea and Aaron M. Ring and Roy L Maute and Anne K Volkmer and Jens-Peter Volkmer and Jie Liu and Jing Shan Lim and Dian Yang and Guido Seitz and Thuyen Nguyen and Di Wu and Kevin Jude and Heather Guerston and Amira A. Barkal and Francesca Trapani and Julie George and John T Poirier and Eric E. Gardner and Linde A. Miles and Elisa de Stanchina and Shane Lofgren and Hannes Vogel and Monte M Winslow and Caroline Dive and Roman K. Thomas and Charles M Rudin and Matt van de Rijn and Ravindra Majeti and K Christopher Garcia and Irving L. Weissman and Julien Sage},
  year={2016}
}
Small-cell lung cancer (SCLC) is a highly aggressive subtype of lung cancer with limited treatment options. CD47 is a cell-surface molecule that promotes immune evasion by engaging signal-regulatory protein alpha (SIRPa), which serves as an inhibitory receptor on macrophages. Here, we found that CD47 is highly expressed on the surface of human SCLC cells; therefore, we investigated CD47-blocking immunotherapies as a potential approach for SCLC treatment. Disruption of the interaction of CD47… CONTINUE READING
32
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 54 REFERENCES

CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2011
VIEW 4 EXCERPTS
HIGHLY INFLUENTIAL

Durable antitumor responses to CD47 blockade require adaptive immune stimulation.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2016
VIEW 1 EXCERPT